Advertisement

Skeletal Radiology

, Volume 47, Issue 11, pp 1517–1522 | Cite as

Surveillance MRI for the detection of locally recurrent Ewing sarcoma seems futile

  • Ömer Kasalak
  • Amelie Dammann
  • Hugo J. A. Adams
  • Jelle Overbosch
  • Rudi A. J. O. Dierckx
  • Paul C. Jutte
  • Thomas C. Kwee
Scientific Article
  • 85 Downloads

Abstract

Purpose

To determine the frequency of locally recurrent Ewing sarcoma on surveillance MRI and the outcome of these patients.

Materials and methods

This retrospective single-center study included all patients with newly diagnosed Ewing sarcoma who underwent surveillance MRI of the primary tumor location after primary treatment between 1997 and 2016.

Results

Thirty-two patients underwent a total of 176 local surveillance MRI scans, yielding an average of 5.5 ± 4.4 MRI scans per patient. Follow-up time of surveillance MRI after completion of primary treatment ranged between 1 and 111 months. Surveillance MRI detected five (15.6%) locally recurrent Ewing sarcomas, at 2, 4, 6, 6, and 7 months after completion of primary treatment, of whom three also had simultaneous recurrent (metastatic) disease elsewhere. Two patients had recurrent metastatic disease without any signs of locally recurrent disease on surveillance MRI. All five patients with locally recurrent disease on surveillance MRI died, at 2, 4, 5, 8, and 9 months after local recurrence detection. Patients with locally recurrent disease had a significantly worse overall survival than patients without locally recurrent disease (log-rank test, P < 0.0001).

Conclusions

A limited number of patients have locally recurrent Ewing sarcoma on surveillance MRI. These patients often have simultaneous recurrent (metastatic) disease elsewhere, and their outcome is poor. Moreover, some patients present without locally recurrent disease on MRI but disease recurrence elsewhere. Therefore, surveillance MRI currently seems to have little value and should be reconsidered, also given the costs and the repeated exposure of surviving patients to gadolinium-based contrast agents.

Keywords

Ewing sarcoma Gadolinium MRI Recurrence Survival 

Notes

Compliance with ethical standards

Conflict of interest

None (all authors).

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

This study was approved by the local institutional review board and because of its retrospective nature the requirement for written informed consent was waived.

References

  1. 1.
    Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–46.CrossRefPubMedGoogle Scholar
  2. 2.
    Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Kauffman WM, Fletcher BD, Hanna SL, Meyer WH. MR imaging findings in recurrent primary osseous Ewing sarcoma. Magn Reson Imaging. 1994;12(8):1147–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Bacci G, Longhi A, Ferrari S, Mercuri M, Barbieri E, Bertoni F, et al. Pattern of relapse in 290 patients with nonmetastatic Ewing’s sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol. 2006;32(9):974–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB, International Society for Magnetic Resonance in M. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16(7):564–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Young DW. What does an MRI scan cost? Healthc Financ Manage. 2015;69(11):46–9.PubMedGoogle Scholar
  7. 7.
    Rossi Espagnet MC, Bernardi B, Pasquini L, Figa-Talamanca L, Toma P, Napolitano A. Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol. 2017;47(10):1345–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Tibussek D, Rademacher C, Caspers J, Turowski B, Schaper J, Antoch G, et al. Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology. 2017;285(1):223–30.CrossRefPubMedGoogle Scholar

Copyright information

© ISS 2018

Authors and Affiliations

  • Ömer Kasalak
    • 1
  • Amelie Dammann
    • 1
  • Hugo J. A. Adams
    • 2
  • Jelle Overbosch
    • 1
  • Rudi A. J. O. Dierckx
    • 1
  • Paul C. Jutte
    • 3
  • Thomas C. Kwee
    • 1
  1. 1.Department of Radiology, Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
  2. 2.Department of Radiology and Nuclear ImagingDeventer HospitalDeventerThe Netherlands
  3. 3.Department of OrthopedicsUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands

Personalised recommendations